We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smokeless Unit & Pricing to Boost Altria's (MO) Q2 Earnings
Read MoreHide Full Article
Altria Group, Inc. (MO - Free Report) is slated to release second-quarter 2019 results on Jul 30, before the opening bell. The company’s earnings missed the Zacks Consensus Estimate by 2.2% in the last reported quarter. Prior to this, the bottom line had surpassed estimates for six straight quarters.
Let’s discuss how things are shaping up for the upcoming quarterly release.
Estimates Reveal Bright Prospects
The Zacks Consensus Estimate for earnings has improved by a penny in the past seven days and is currently stable at $1.10. The projected figure indicates 8.9% growth from the year-ago quarter’s level. The consensus mark for revenues is pegged at $5,047 million, suggesting a rise of 3.4% from the year-ago quarter’s level.
Altria Group, Inc. Price, Consensus and EPS Surprise
Altria’s smokeless unit is rapidly expanding on the back of consumers’ growing interests in low risk tobacco alternatives. Its flagship MarkTen and Green Smoke e-vapor products are performing strongly in this category. Also, the company’s partnership with JUUL — a renowned e-cigarettes player — has radically boosted its presence in the reduced risk tobacco products (RRPs) space. Moreover, the company’s partnership with Philip Morris (PM - Free Report) , pertaining to the sale of IQOS in the United States, has been approved by the FDA. Altria has undertaken steps to expand into the booming cannabis industry, which is evident from the acquisition of stakes in Cronos Group (CRON - Free Report) . Well, these prudent partnerships are likely to boost the smokeless unit’s performance and support second-quarter results. Other tobacco players like British American Tobacco (BTI - Free Report) have also undertaken endeavors to boost presence in the RRPs space.
Moving on, product pricing is expected to be a vital revenue driver during the quarter. Markedly, price hikes enable Altria to cushion impacts from high taxes levied on tobacco products.
Also, the company is progressing well its cost-reduction program, which is aimed to rake in annualized cost savings of nearly $575 million by the end of the year 2019. The program also focuses on reducing workforce and third-party spending. These initiatives are likely to make a positive impact on the forthcoming results.
On the flip side, matters have been gloomy in the company’s cigarette category, thanks to declining sales volumes. Cigarette sales are being impaired by fading consumer enthusiasm and regulatory hurdles. Nevertheless, we expect Altria to tide over such hurdles on the back of gains from the smokeless unit and efficient product pricing.
Zacks Model
Our proven model shows that Altria is likely to beat earnings estimates this quarter. A stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can see the complete list of today’s Zacks #1 Rank stocks here.
Altria carries a Zacks Rank #3 and has an Earnings ESP of +0.91%, which makes us reasonably confident about an earnings beat. You may uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Smokeless Unit & Pricing to Boost Altria's (MO) Q2 Earnings
Altria Group, Inc. (MO - Free Report) is slated to release second-quarter 2019 results on Jul 30, before the opening bell. The company’s earnings missed the Zacks Consensus Estimate by 2.2% in the last reported quarter. Prior to this, the bottom line had surpassed estimates for six straight quarters.
Let’s discuss how things are shaping up for the upcoming quarterly release.
Estimates Reveal Bright Prospects
The Zacks Consensus Estimate for earnings has improved by a penny in the past seven days and is currently stable at $1.10. The projected figure indicates 8.9% growth from the year-ago quarter’s level. The consensus mark for revenues is pegged at $5,047 million, suggesting a rise of 3.4% from the year-ago quarter’s level.
Altria Group, Inc. Price, Consensus and EPS Surprise
Altria Group, Inc. price-consensus-eps-surprise-chart | Altria Group, Inc. Quote
Smokeless Unit, Pricing & Savings: Key Catalysts
Altria’s smokeless unit is rapidly expanding on the back of consumers’ growing interests in low risk tobacco alternatives. Its flagship MarkTen and Green Smoke e-vapor products are performing strongly in this category. Also, the company’s partnership with JUUL — a renowned e-cigarettes player — has radically boosted its presence in the reduced risk tobacco products (RRPs) space. Moreover, the company’s partnership with Philip Morris (PM - Free Report) , pertaining to the sale of IQOS in the United States, has been approved by the FDA. Altria has undertaken steps to expand into the booming cannabis industry, which is evident from the acquisition of stakes in Cronos Group (CRON - Free Report) . Well, these prudent partnerships are likely to boost the smokeless unit’s performance and support second-quarter results. Other tobacco players like British American Tobacco (BTI - Free Report) have also undertaken endeavors to boost presence in the RRPs space.
Moving on, product pricing is expected to be a vital revenue driver during the quarter. Markedly, price hikes enable Altria to cushion impacts from high taxes levied on tobacco products.
Also, the company is progressing well its cost-reduction program, which is aimed to rake in annualized cost savings of nearly $575 million by the end of the year 2019. The program also focuses on reducing workforce and third-party spending. These initiatives are likely to make a positive impact on the forthcoming results.
On the flip side, matters have been gloomy in the company’s cigarette category, thanks to declining sales volumes. Cigarette sales are being impaired by fading consumer enthusiasm and regulatory hurdles. Nevertheless, we expect Altria to tide over such hurdles on the back of gains from the smokeless unit and efficient product pricing.
Zacks Model
Our proven model shows that Altria is likely to beat earnings estimates this quarter. A stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can see the complete list of today’s Zacks #1 Rank stocks here.
Altria carries a Zacks Rank #3 and has an Earnings ESP of +0.91%, which makes us reasonably confident about an earnings beat. You may uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>